Lncyt
Latest round
- Series C
Last raised
- Jul 2025
Total raised
- Undisclosed
Investors
- 3
About Lncyt
Established in 2021 and based in Yantai, China, Lncyt is a drug discovery company that focuses on developing innovative nuclear drugs for diagnostic and therapeutic integration. The company has partnerships with the National University of Singapore (NUS), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Tumor Hospital, and Beijing Tumor Hospital. It has a 6,500-square-meter integrated laboratory for targeted drug synthesis, radiolabeling, preclinical cell and animal experiments, and molecular imaging., Ltd. The company’s main business is the development of innovative nuclear medicines, focusing on Class 1 integrated diagnostic and therapeutic radiopharmaceuticals. Its products are used in the field of oncology, covering a spectrum of cancer types, including prostate cancer, solid tumors, gliomas, and neuroendocrine tumors. The company generates revenue by providing targeted nuclear medicine solutions and integrated diagnostic and therapeutic services.
Who invested in Lncyt
3 investors across 1 round
See all investors in Lncyt
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jul 17, 2025
Amount
Undisclosed
Investors
Questions about Lncyt
Who invested in Lncyt?
Lncyt has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lncyt raised?
Lncyt has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lncyt last raise money?
Lncyt's most recent round on record is a Series C, in Jul 2025.
What does Lncyt do?
Established in 2021 and based in Yantai, China, Lncyt is a drug discovery company that focuses on developing innovative nuclear drugs for diagnostic and therapeutic integration.
Where is Lncyt headquartered?
Lncyt is headquartered in Yantai, China.
Which VCs invest in companies like Lncyt?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Lncyt's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Lncyt? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.